RS 93427 007

Drug Profile

RS 93427 007

Alternative Names: RS 93427

Latest Information Update: 07 Nov 1997

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Class Anti-ischaemics; Antihyperlipidaemics; Antithrombotics; Prostaglandins; Small molecules
  • Mechanism of Action Prostacyclin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 07 Nov 1997 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
  • 07 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 24 Oct 1994 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top